Mateusz Adam Krzyscik
Overview
Explore the profile of Mateusz Adam Krzyscik including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
108
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nawrocka D, Krzyscik M, Sluzalska K, Otlewski J
Int J Mol Sci
. 2023 Jun;
24(12).
PMID: 37373291
Targeting fibroblast growth factor receptor 1 (FGFR1) is a promising therapeutic strategy for various cancers associated with alterations in the FGFR1 gene. In this study, we developed a highly cytotoxic...
2.
Pozniak M, Zukowska D, Gedaj A, Krzyscik M, Porebska N, Zakrzewska M, et al.
Int J Mol Sci
. 2022 Aug;
23(15).
PMID: 35955648
Precise anticancer therapies employing cytotoxic conjugates constitute a side-effect-limited, highly attractive alternative to commonly used cancer treatment modalities, such as conventional chemotherapy, radiotherapy or surgical interventions. Receptor tyrosine kinases are...
3.
Jendryczko K, Rzeszotko J, Krzyscik M, Kocyla A, Szymczyk J, Otlewski J, et al.
Mol Pharm
. 2022 Apr;
19(5):1422-1433.
PMID: 35389227
With a wide range of available cytotoxic therapeutics, the main focus of current cancer research is to deliver them specifically to the cancer cells, minimizing toxicity against healthy tissues. Targeted...
4.
Jendryczko K, Rzeszotko J, Krzyscik M, Szymczyk J, Otlewski J, Szlachcic A
Front Pharmacol
. 2021 Dec;
12:748936.
PMID: 34867353
Targeted therapies are a promising alternative to conventional chemotherapy, with an increasing number of therapeutics targeting specific molecular aberrancies in cancer cells. One of the emerging targets for directed cancer...
5.
Porebska N, Knapik A, Pozniak M, Krzyscik M, Zakrzewska M, Otlewski J, et al.
Biomacromolecules
. 2021 Dec;
22(12):5349-5362.
PMID: 34855396
Fibroblast growth factor receptor 1 (FGFR1) is an integral membrane protein that transmits prolife signals through the plasma membrane. Overexpression of FGFR1 has been reported in various tumor types, and...
6.
Pozniak M, Porebska N, Jastrzebski K, Krzyscik M, Kucinska M, Zarzycka W, et al.
J Biomed Sci
. 2021 Oct;
28(1):69.
PMID: 34635096
Background: Overexpression of FGFR1 is observed in numerous tumors and therefore this receptor constitutes an attractive molecular target for selective cancer treatment with cytotoxic conjugates. The success of cancer therapy...
7.
Pozniak M, Porebska N, Krzyscik M, Sokolowska-Wedzina A, Jastrzebski K, Sochacka M, et al.
Mol Med
. 2021 May;
27(1):46.
PMID: 33962559
Background: Antibody drug conjugates (ADCs) represent one of the most promising approaches in the current immuno-oncology research. The precise delivery of cytotoxic drugs to the cancer cells using ADCs specific...
8.
Porebska N, Pozniak M, Krzyscik M, Knapik A, Czyrek A, Kucinska M, et al.
Int J Biol Macromol
. 2021 Mar;
180:470-483.
PMID: 33745974
Fibroblast growth factor receptors (FGFRs) are integral membrane proteins involved in various biological processes including proliferation, migration and apoptosis. There are a number of regulatory mechanisms of FGFR signaling, which...
9.
Krzyscik M, Sokolowska-Wedzina A, Jendryczko K, Pozniak M, Nawrocka D, Porebska N, et al.
J Vis Exp
. 2021 Jan;
(167).
PMID: 33491672
Cancer is currently the second most common cause of death worldwide. The hallmark of cancer cells is the presence of specific marker proteins such as growth factor receptors on their...
10.
Nawrocka D, Krzyscik M, Opalinski L, Zakrzewska M, Otlewski J
Int J Mol Sci
. 2020 Jun;
21(11).
PMID: 32526859
Fibroblast growth factor 2 (FGF2) is a heparin-binding growth factor with broad mitogenic and cell survival activities. Its effector functions are induced upon the formation of 2:2 FGF2:FGFR1 tetrameric complex....